Joost L. Boormans

6.3k total citations · 2 hit papers
128 papers, 2.4k citations indexed

About

Joost L. Boormans is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joost L. Boormans has authored 128 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Surgery, 35 papers in Oncology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joost L. Boormans's work include Bladder and Urothelial Cancer Treatments (98 papers), Urinary and Genital Oncology Studies (70 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Joost L. Boormans is often cited by papers focused on Bladder and Urothelial Cancer Treatments (98 papers), Urinary and Genital Oncology Studies (70 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Joost L. Boormans collaborates with scholars based in Netherlands, United States and Canada. Joost L. Boormans's co-authors include Jan Trapman, Ellen C. Zwarthoff, Ronald de Wit, Karin G. Hermans, Delila Gasi Tandefelt, Kim E.M. van Kessel, Joep J. de Jong, Paul C.M.S. Verhagen, Ashish M. Kamat and Guido Jenster and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Joost L. Boormans

118 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →
European Association of Urology Guidelines on Testicular Cancer: 2023 Update

2023 99 citations Joost L. Boormans, Stefanie Fischer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joost L. Boormans Netherlands	27	1.5k	830	732	584	308	128	2.4k
Darrel Drachenberg Canada	19	677 0.4×	773 0.9×	438 0.6×	378 0.6×	213 0.7×	99	1.5k
Eric Kauffman United States	19	594 0.4×	722 0.9×	730 1.0×	256 0.4×	284 0.9×	76	1.7k
Steffen Rausch Germany	21	476 0.3×	564 0.7×	497 0.7×	292 0.5×	257 0.8×	122	1.4k
Hervé Wallerand France	22	808 0.5×	489 0.6×	666 0.9×	353 0.6×	181 0.6×	68	1.6k
R. J. Amato United States	20	816 0.5×	943 1.1×	779 1.1×	588 1.0×	442 1.4×	68	2.0k
Cynthia Kuk Canada	21	765 0.5×	389 0.5×	256 0.3×	306 0.5×	157 0.5×	42	1.5k
Thorsten Ecke Germany	22	681 0.4×	417 0.5×	414 0.6×	288 0.5×	200 0.6×	107	1.4k
Stefan Zastrow Germany	21	323 0.2×	708 0.9×	509 0.7×	290 0.5×	196 0.6×	57	1.3k
Harri Juusela Finland	18	504 0.3×	826 1.0×	338 0.5×	403 0.7×	241 0.8×	34	1.4k
Brigitte Duclos France	20	531 0.3×	769 0.9×	627 0.9×	508 0.9×	280 0.9×	52	1.6k

Countries citing papers authored by Joost L. Boormans

Since Specialization

Citations

This map shows the geographic impact of Joost L. Boormans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joost L. Boormans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joost L. Boormans more than expected).

Fields of papers citing papers by Joost L. Boormans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joost L. Boormans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joost L. Boormans. The network helps show where Joost L. Boormans may publish in the future.

Co-authorship network of co-authors of Joost L. Boormans

This figure shows the co-authorship network connecting the top 25 collaborators of Joost L. Boormans. A scholar is included among the top collaborators of Joost L. Boormans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joost L. Boormans. Joost L. Boormans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations

Hoogstraten, Lisa M.C. van, Sebastiaan Remmers, Jorg R. Oddens, et al.. (2024). Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer – a contemporary cohort. European Urology Oncology. 8(2). 249–252. 1 indexed citations

Robbrecht, Debbie, Alberto Gil-Jimenez, Hayri E. Balcıoğlu, et al.. (2024). Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nature Communications. 15(1). 1349–1349. 6 indexed citations

Jong, Joep J. de, Tarek A. Bismar, Stephen A. Boorjian, et al.. (2024). Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. Urologic Oncology Seminars and Original Investigations. 42(6). 177.e5–177.e14. 1 indexed citations

Zuiverloon, Tahlita C.M., et al.. (2024). Selecting the right treatment: Health outcome priorities in older patients with bladder cancer. Journal of Geriatric Oncology. 15(6). 101811–101811. 1 indexed citations

Boormans, Joost L., Richard Sylvester, Lynn Anson‐Cartwright, et al.. (2023). Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. European Urology Oncology. 7(3). 537–543. 9 indexed citations

Boormans, Joost L., Richard Sylvester, Lynn Anson‐Cartwright, et al.. (2023). European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.. Journal of Clinical Oncology. 41(6_suppl). 410–410. 2 indexed citations

Salhi, Yazan Al, Debbie Robbrecht, Ronald de Wit, et al.. (2023). The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial. BMC Cancer. 23(1). 539–539. 1 indexed citations

Robbrecht, Debbie, Mandy van Brakel, Joost L. Boormans, et al.. (2022). A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. Cancer Immunology Immunotherapy. 72(3). 759–767. 9 indexed citations

10.

Jong, Joep J. de, Hans Stoop, Joost L. Boormans, & Geert J.L.H. van Leenders. (2021). PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(4). 705–713. 4 indexed citations

11.

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →

12.

Richters, Anke, Joost L. Boormans, Michiel S. van der Heijden, et al.. (2021). Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study. European Urology Open Science. 33. S391–S391. 1 indexed citations

13.

Jong, Joep J. de, Vikram M. Narayan, Andrea A. Cronican, et al.. (2021). Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. American Journal of Clinical Pathology. 156(5). 895–905. 7 indexed citations

14.

Mark, Marianne van der, et al.. (2020). Trends in incidence and survival of upper Urinary Tract Urothelial Carcinoma (UTUC) diagnosed between 1993-2017 in the Netherlands: A study on 13,438 patients. European Urology Open Science. 19. e2186–e2187. 1 indexed citations

15.

Horst, Geertje van der, Maaike H. van der Mark, L. M. Appelman, et al.. (2020). Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. Molecular Oncology. 14(12). 3121–3134. 8 indexed citations

16.

Mason, Andrew S., Geert J.L.H. van Leenders, Tahlita C.M. Zuiverloon, et al.. (2020). The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer. 148(4). 981–987. 10 indexed citations

17.

Putte, Elisabeth E. Fransen van de, Judith Bosschieter, Theodorus van der Kwast, et al.. (2018). The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non‐muscle‐invasive bladder cancer. British Journal of Urology. 122(6). 978–985. 23 indexed citations

18.

Voskuilen, Charlotte S., Laura S. Mertens, Simon Horenblas, et al.. (2018). Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3‐4aN0M0 compared to cT2N0M0 bladder cancer. International Journal of Cancer. 144(6). 1453–1459. 22 indexed citations

19.

Hermans, Karin G., Joost L. Boormans, Delila Gasi Tandefelt, et al.. (2009). Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer. Clinical Cancer Research. 15(20). 6398–6403. 69 indexed citations

20.

Hermans, Karin G., Hetty A. van der Korput, Ronald van Marion, et al.. (2008). Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate Cancer. Cancer Research. 68(18). 7541–7549. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact